What are the indications and criteria for deep brain stimulation in treatment‑resistant major depressive disorder?

Deep Brain Stimulation for Treatment-Resistant Major Depressive Disorder

Deep brain stimulation (DBS) should be considered only for patients with severe, treatment-resistant major depressive disorder who have failed at least two adequate antidepressant trials of different mechanisms of action (minimum licensed dose for ≥4 weeks each), with documented failure of other evidence-based interventions including ECT or rTMS, and who are managed by experienced multidisciplinary teams at specialized centers. 1, 2

Defining Treatment-Resistant Depression (TRD)

Before considering DBS, you must establish true treatment resistance:

• Minimum requirement: Failure of at least 2 adequate antidepressant trials from different pharmacological classes (based on Neuroscience-based Nomenclature) 1
• Adequate trial defined as: Minimum licensed dose for ≥4 weeks duration 1
• Severity threshold: Moderate to severe depression confirmed by structured assessment (MADRS or HAM-D) 1, 3
• Documentation: Must be prospectively confirmed or based on medical records, not patient recall alone 1

Exclusion Criteria Before DBS Consideration

Absolute exclusions 1:

• Bipolar depression (not unipolar MDD)
• Active severe substance use disorder not in remission
• Personality disorders with onset documented as independent and antecedent to MDD diagnosis
• Prior failure of other invasive neurostimulation (previous DBS or vagus nerve stimulation) 1

Not exclusions 1:

• Prior ECT or rTMS failure
• Multiple failed medication trials
• Failed augmentation strategies
• Comorbid mild-moderate substance use disorder
• Any depression specifier (melancholic, atypical, anxious, psychotic, mixed)

Hierarchical Treatment Algorithm Before DBS

You must document failure of these interventions first 4, 5:

1. Pharmacotherapy: Minimum 2 adequate trials of different antidepressant classes
2. Augmentation/combination: Trials with buspirone, bupropion, or switching strategies
3. Ketamine/esketamine: For patients failing multiple adequate trials 4
4. rTMS: Left prefrontal stimulation (30 sessions) 4
5. ECT: Particularly for severe, life-threatening symptoms 6

Only after documented failure of these less invasive options should DBS be considered 2.

DBS-Specific Requirements

Mandatory institutional requirements 2:

• Experienced multidisciplinary team (neurosurgery, psychiatry, neuropsychology)
• Capacity for long-term follow-up and monitoring
• Documented informed consent respecting patient autonomy
• Systematic reporting of effects and adverse events for all patients

Patient selection criteria 2, 7:

• Severe, persistent symptoms significantly impairing function
• Documented refractoriness to standard treatments
• Absence of active suicidality requiring immediate intervention
• Cognitive capacity for informed consent

Evidence for Efficacy and Targets

Current evidence base 8, 9:

• Long-term response rates: 40-70% across studies
• Time to 50% improvement: approximately 23 months
• Long-term response rate: 48%; remission rate: 35%

Brain targets (in order of evidence strength) 9:

1. Medial forebrain bundle (MFB): Greatest reduction in symptoms (86% responder rate)
2. Subcallosal cingulate gyrus (SCG/Cg25): Well-studied, ~50% response
3. Ventral capsule/ventral striatum (VC/VS): Comparable efficacy to SCG
4. Nucleus accumbens (NAcc): Under investigation

Critical Caveats

Major limitation: Sham-controlled data do not consistently demonstrate superiority over placebo, suggesting significant placebo effects from the procedure itself 8. Open-label trials show significantly greater effects than randomized controlled trials 8.

Safety profile 7, 10, 11:

• Wound infection
• Hypomania induction
• Rare suicide events
• Generally well-tolerated with cognitive safety

Practical barriers:

• Invasive procedure requiring neurosurgical expertise
• High cost
• Still considered experimental/investigational 10
• Limited availability at specialized centers only

When NOT to Pursue DBS

Do not consider DBS if:

• Patient has not exhausted pharmacotherapy, psychotherapy, ECT, and rTMS options
• Depression is part of bipolar disorder
• Active severe substance use disorder present
• Prior DBS or VNS has already failed 1
• Patient lacks capacity for informed consent or long-term follow-up
• Multidisciplinary team and institutional infrastructure unavailable 2

Bottom line: DBS remains an investigational intervention reserved for the most severe, truly treatment-refractory cases after systematic failure of all standard evidence-based treatments, and should only be performed in specialized research settings with rigorous patient selection and monitoring protocols. 2, 7, 8